Anti-MAPKBP1 Rabbit Polyclonal Antibody for WB and ELISA - O60336

Core Product Specifications and Parameters

Biological Background: MAPKBP1 Function and Localization

• Mitogen-activated protein kinase-binding protein 1 (MAPKBP1), also known as JNK-binding protein 1 (JNKBP-1), is encoded by the MAPKBP1 gene, which undergoes alternative splicing to produce multiple isoforms.
• It functions as a negative regulator of NOD2 signaling, suppressing NF-kappa-B activation, IL8 secretion, and antibacterial responses (PubMed:22700971). Related references: PMID:22700971
• MAPKBP1 is involved in the JNK signaling pathway (By similarity).
• Subcellular localization includes the cytoplasm, nucleus, and spindle poles of the cytoskeleton.
• Expressed in intestinal mucosa (epithelial, endothelial, smooth muscle, and immune cells) and kidney.
• Post-translational modifications include acetylation and phosphorylation; the protein contains WD repeats and is associated with disease variants linked to nephronophthisis.

Experimental Guidance and Technical Tips

• The immunogen is a synthetic peptide from the N-terminal region (aa 1–100); it may detect full-length MAPKBP1 and possibly N-terminal isoforms—validate specificity in your target tissue or cell line.
• For Western blotting, the predicted molecular weight is 164 kDa; use an appropriate percentage of SDS-PAGE gel (e.g., 8% or gradient gel) and optimize transfer conditions for high-molecular-weight proteins.
• In ELISA, the immunizing peptide or recombinant MAPKBP1 protein can serve as a positive control; consider indirect or sandwich ELISA formats depending on your assay needs.
• The antibody is reported to cross-react with mouse and rat MAPKBP1; for other species, check sequence homology of the immunogen region.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio partners with diagnostic manufacturers and research laboratories to streamline procurement of IVD-grade raw materials. This MAPKBP1 polyclonal antibody supports studies in innate immunity and cell signaling, and we offer complementary validated antibody pairs, monoclonal alternatives, and bulk ancillary reagents. For rare-target sourcing or custom development, our technical team provides end-to-end support from concept to clinic.